Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.63 |
| ▸ | TK2 | O00142 | 2/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netivudine SCHEMBL913358 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL18052692 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL6153401 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL112727 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL9538356 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL1585773 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL462884 | 0.97 | PYGM (0.60) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL22028728 | 0.92 | P2RY6 (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21276349 | 0.91 | PYGM (0.51) | PYGMTK2DNPH1P2RY2TSHR | |
| SCHEMBL1060638 | 0.90 | PYGM (0.51) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10522 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4740010-A1 | NEGATIVE TUNE STANDARD FOR MASS SPECTROMETRY | Agilent Technologies, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | claimed |
| US-20260078356-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12577554-B2 | Methods for purification of messenger RNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260028616-A1 | METHODS AND APPARATUS FOR DUPLEX NUCLEOTIDE PURIFICATION | AGILENT TECHNOLOGIES, INC. (US) | 2026-01-29 | — | — | US | claimed |
| EP-4677078-A1 | MANUFACTURE OF MESSENGER RNA WITH KP34 POLYMERASE | Sanofi Pasteur Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| JP-2002523335-A | — | — | 2002-07-30 | — | — | JP | claimed |
| EP-1102842-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-30 | — | — | EP | claimed |
| US-6056859-A | Method and apparatus for staining immobilized nucleic acids | LOCKHEED MARTIN ENERGY RESEARCH CORPORATION (US) | 2000-05-02 | — | — | US | claimed |
| WO-2000008140-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | claimed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | claimed |
| JP-2682739-B2 | — | — | 1997-11-26 | — | — | JP | claimed |
| EP-0550580-A1 | URACIL REDUCTASE INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-14 | — | — | EP | claimed |
| EP-0539442-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-05-05 | — | — | EP | claimed |
| WO-1992004901-A1 | URACIL REDUCTASE INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | claimed |
| WO-1992001452-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-02-06 | — | — | WO | claimed |